Yaokang Biotech said on July 21 it signed a strategic cooperation memorandum of
understanding with South Korea clinical-trial sample-analysis firm GCCL. The
partners will jointly offer integrated drug discovery and development services
to global pharmaceutical and biotech companies, initially covering oncology and
immunology and prioritizing in vivo CAR‑T therapies.
